Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1GSK3AGSK3BHRH1HRH2HTR7IDH1IDH2IMPA1IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | SLC13A5 | Q86YT5 | 6/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL6238060 | 0.87 | CA4 (0.63) | CA4GAAMAPTALDH1A1CA2 | |
| Citric Acid SCHEMBL6238058 | 0.87 | CA4 (0.63) | CA4GAAMAPTALDH1A1CA2 | |
| Citric Acid SCHEMBL29054134 | 0.84 | CA4 (0.57) | CA4GAAMAPTALDH1A1TDP1 | |
| Citric Acid SCHEMBL5064884 | 0.83 | ALDH1A1 (0.60) | SLC13A5GAAMAPTCYP2C19HIF1A | |
| Citric Acid SCHEMBL29054131 | 0.81 | ALDH1A1 (0.58) | SLC13A5GAAMAPTCYP2C19HIF1A | |
| Citric Acid SCHEMBL73102 | 0.80 | CA4 (0.67) | CA4SLC13A5CYP2C19HIF1AALDH1A1 | |
| Citric Acid SCHEMBL2890971 | 0.80 | CA4 (0.67) | CA4SLC13A5CYP2C19HIF1AALDH1A1 | |
| Citric Acid SCHEMBL10477647 | 0.80 | CA4 (0.67) | CA4SLC13A5CYP2C19HIF1AALDH1A1 | |
| Citric Acid SCHEMBL106889 | 0.79 | CA4 (0.41) | CA4SLC13A5CYP2C19HIF1AALDH1A1 | |
| Citric Acid SCHEMBL104572 | 0.79 | CA4 (0.41) | CA4SLC13A5CYP2C19HIF1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1119346-B1 | RNA CANCER VACCINE AND METHODS FOR ITS USE | WAYNE JOHN CANCER INST (US) | 2005-06-01 | — | — | EP | disclosed |
| US-6472375-B1 | DNA vaccine and methods for its use | JOHN WAYNE CANCER INSTITUTE | 2002-10-29 | — | — | US | disclosed |
| US-6432925-B1 | TUMOR ANTIGEN | JOHN WAYNE CANCER INSTITUTE | 2002-08-13 | — | — | US | disclosed |
| EP-1119346-A2 | RNA CANCER VACCINE AND METHODS FOR ITS USE | John Wayne Cancer Institute (US) | 2001-08-01 | — | — | EP | disclosed |
| EP-1108028-A2 | DNA CANCER VACCINE AND METHODS FOR ITS USE | John Wayne Cancer Institute (US) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000012127-A2 | DNA CANCER VACCINE AND METHODS FOR ITS USE | JOHN WAYNE CANCER INSTITUTE (US) | 2000-03-09 | — | — | WO | disclosed |
| WO-1999052503-A2 | RNA CANCER VACCINE AND METHODS FOR ITS USE | JOHN WAYNE CANCER INSTITUTE (US) | 1999-10-21 | — | — | WO | disclosed |